TURNOVER (x1000 DKK)
NET PROFIT (x1000 DKK)
EMPLOYEES
Sprint Bioscience AB
Closing information (x1000 DKK)
| Closing information | 2024/12 | 2023/12 | 2022/12 |
| Turnover |
42,631
|
33,909
|
55 |
| Financial expenses |
26
|
260
|
1 |
| Earnings before taxes |
-11,870
|
-294
|
-40,208 |
| EBITDA |
-12,151
|
-267
|
-40,176 |
| Total assets |
27,313
|
41,897
|
25,007 |
| Current assets |
24,188
|
38,871
|
23,309 |
| Current liabilities |
21,291
|
23,242
|
6,170 |
| Equity capital |
6,022
|
18,655
|
18,836 |
| - share capital |
4,535
|
4,690
|
4,664 |
| Employees (average) |
37
|
28
|
34 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Solvency |
22.0%
|
44.5%
|
75.3% |
| Turnover per employee |
1,152
|
1,211
|
2 |
| Profit as a percentage of turnover |
-27.8%
|
-0.9%
|
-73105.5% |
| Return on assets (ROA) |
-43.4%
|
-0.1%
|
-160.8% |
| Current ratio |
113.6%
|
167.2%
|
377.8% |
| Return on equity (ROE) |
-197.1%
|
-1.6%
|
-213.5% |
| Change turnover |
9,843
|
33,854
|
-23,409 |
| Change turnover % |
30%
|
60725%
|
-100% |
| Chg. No. of employees |
9
|
-6
|
3 |
| Chg. No. of employees % |
32%
|
-18%
|
10% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.